An exploration of the potential mechanisms and translational potential of five medicinal plants for applications in Alzheimer’s disease

American Journal of Neurodegenerative Diseases

Volumn 2, Issue 2, 2013, Pages 70-88

  Shakir, Taner ^a   Coulibaly, Ahmed Y ^b   Kehoe, Patrick G ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITÉ DE OUAGADOUGOU   (Burkina Faso)

Author keywords

Alzheimer s disease; Catharanthus roseus; Cholinergic; Diabetes; Erythrina senegalensis; Hypertension; Neuroprotective; Oxidative stress; Scoparia dulcis; Sesamum indicum; Vigna unguiculata

Indexed keywords

1,1 DIPHENYL 2 PICRYLHYDRAZYL; ACETYLCHOLINE; ACETYLCHOLINESTERASE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA SYNUCLEIN; AMYLOID PRECURSOR PROTEIN; ANGIOTENSIN II; BETA SECRETASE; CALCIUM CHANNEL BLOCKING AGENT; CATALASE; CHOLINERGIC RECEPTOR; CHOLINESTERASE; DICHLOROMETHANE; FLAVONOID; GAMMA SECRETASE; GLUCOSE; GLUTAMIC ACID; GLUTATHIONE; NERVE GROWTH FACTOR; NICOTINIC RECEPTOR; NITRIC OXIDE; NORADRENALIN; PHENOL; REACTIVE OXYGEN METABOLITE; SERPENTINE; SUPEROXIDE DISMUTASE; TAU PROTEIN; TERPENOID; TETRAHYDROCANNABINOL; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANTIDIABETIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ANTIOXIDANT ACTIVITY; CATHARANTHUS ROSEUS; CHOLINERGIC ACTIVITY; CLINICAL TRIAL (TOPIC); COWPEA; DIABETES MELLITUS; DIET SUPPLEMENTATION; ERTHYTHRINA SENEGALENSIS; GINKGO BILOBA; HUMAN; HYPERTENSION; MEDICINAL PLANT; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; SCOPARIA DULCIS; SESAME;

EID: 84892748527     PISSN: None     EISSN: 2165591X     Source Type: Journal    
DOI: None     Document Type: Review

References (144)

1. Coleman PD and Yao PJ. Synaptic slaughter in Alzheimer's disease. Neurobiol Aging 2003; 24: 1023-1027.
2. Fox N. When, where, and how does Alzheimer's disease start? Lancet Neurol 2012; 11: 1017- 1018.
3. Fox NC, Scahill RI, Crum WR, Rossor MN. Correlation between rates of brain atrophy and cognitive decline in AD. Neurology 1999; 52: 1687-1689.
4. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, Trojanowski JQ, Toga AW, Beckett L. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement 2005; 1: 55-66.
5. Schneider LS, Insel PS, Weiner MW. Treatment With Cholinesterase Inhibitors and Memantine of Patients in the Alzheimer's Disease Neuroimaging InitiativeTreatment with ChEIs and Memantine in ADNI. Arch Neurol 2011; 68: 58- 66.
6. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 2011; 377: 1019-1031.
7. Love S, Miners S, Palmer J, Chalmers K, Kehoe P. Insights into the pathogenesis and pathogenicity of cerebral amyloid angiopathy. Front Biosci 2009; 14: 4778-4792.
8. Doraiswamy PM, Leon J, Cummings JL, Marin D and Neumann PJ. Prevalence and impact of medical comorbidity in Alzheimer's disease. J Gerontol A Biol Sci Med Sci 2002; 57: 173-177.
9. Alzheimers Research UK. Dementia Statistics 2012.
10. Alzheimers Association. Factsheet 2012.
11. Castellani RJ, Rolston RK and Smith MA. Alzheimer disease. Dis Mon 2010; 56: 484-546.
12. Solfrizzi V, Panza F, Frisardi V, Seripa D, Logroscino G, Imbimbo BP and Pilotto A. Diet and Alzheimer's disease risk factors or prevention: the current evidence. Expert Rev Neurother 2011; 11: 677-708.
13. Dentali F, Romualdi E, Ageno W, Cappellini MD and Mannucci PM. Thalassemia trait and arterial thromboembolic events: a systematic review and a meta-analysis of the literature. J Thromb Haemost 2011; 9: 917-921.
14. Joas E, Bäckman K, Gustafson D, Ostling S, Waern M, Guo X and Skoog I. Blood pressure trajectories from midlife to late life in relation to dementia in women followed for 37 years. Hypertension 2012; 59: 796-801.
15. Qiu C, De Ronchi D and Fratiglioni L. The epidemiology of the dementias: an update. Curr Opin Psychiatry 2007; 20: 380-385.
16. Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, Andrews H and Mayeux R. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348: 429-432.
17. Gandy S and Duff K. Post-menopausal estrogen deprivation and Alzheimer's disease. Exp Gerontol 2000; 35: 503-511.
18. Serpell LC. Alzheimer's amyloid fibrils: structure and assembly. Biochim Biophys Acta 2000; 1502: 16-30.
19. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G and Citron M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286: 735-741.
20. Miners JS, Barua N, Kehoe PG, Gill S and Love S. Aβ-degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol 2011; 70: 944-959.
21. Shankar GM, Li S, Mehta TH and Garcia-Munoz A. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008; 14: 837- 842.
22. Auld DS, Kornecook TJ, Bastianetto S and Quirion R. Alzheimer's disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 2002; 68: 209-245.
23. Kerr F, Rickle A, Nayeem N, Brandner S, Cowburn RF and Lovestone S. PTEN, a negative regulator of PI3 kinase signalling, alters tau phosphorylation in cells by mechanisms independent of GSK-3. FEBS Letts 2006; 580: 3121-3128.
24. Sofola O, Kerr F, Rogers I, Killick R, Augustin H, Gandy C, Allen MJ, Hardy J, Lovestone S and Partridge L. Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease. PLoS Genet 2010; 6: 9.
25. Andreadis A. Tau splicing and the intricacies of dementia. J Cell Physiol 2012; 227: 1220- 1225.
26. Roy S, Zhang B, Lee V and Trojanowski JQ. Axonal transport defects: a common theme in neurodegenerative diseases. Acta Neuropathologica 2005; 109: 5-13.
27. Kadowaki H, Nishitoh H and Urano F. Amyloid β induces neuronal cell death through ROS-mediated ASK1 activation. Cell Death Differ 2005; 12: 19-24.
28. Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA and Markesbery WR. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci U S A 1991; 88: 10540-10543.
29. Markesbery WR and Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 1998; 19: 33-36.
30. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Odén A and Svanborg A. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-1145.
31. Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, Nelson J, Davis DG, Hardman J, Foley DJ and Launer LJ. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study. Neurobiol Aging 2000; 21: 57-62.
32. Davies NM, Kehoe PG, Ben-Shlomo Y and Martin RM. Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimers Dis 2011; 26: 699-708.
33. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE and Wolozin B. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010; 340: 5465.
34. Hajjar IM, Keown M, Lewis P and Almor A. Angiotensin converting enzyme inhibitors and cognitive and functional decline in patients with Alzheimer's disease: an observational study. Am J Alzheimers Dis Other Demen 2008; 23: 77-83.
35. Ohrui T, Tomita N, Sato-Nakagawa T and Matsui T. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004; 63: 1324-1325.
36. Rozzini L, Chilovi BV and Trabucchi M. Antihypertensive medications influence the rate of conversion from mild cognitive impairment to Alzheimer disease. Arch Neurol 2008; 65: 993-994.
37. Solfrizzi V, Scafato E, Frisardi V, Seripa D, Logroscino G, Kehoe PG, Imbimbo BP, Baldereschi M, Crepaldi G, Di Carlo A, Galluzzo L, Gandin C, Inzitari D, Maggi S, Pilotto A, Panza F; Italian Longitudinal Study on Aging Working Group. Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. AGE (Dordr) 2011; 35; 441-453.
38. Goodison WV, Frisardi V and Kehoe PG. Calcium Channel Blockers and Alzheimer's Disease: Potential Relevance in Treatment Strategies of Metabolic Syndrome. J Alzheimers Dis 2012; 30: 269-282.
39. Kehoe PG and Passmore PA. The renin-angiotensin system and antihypertensive drugs in Alzheimer's disease: current standing of the angiotensin hypothesis? J Alzheimers Dis 2012; 30: 251-268.
40. Lee PH, Bang OY, Hwang EM, Lee JS, Joo US, Mook-Jung I and Huh K. Circulating beta amyloid protein is elevated in patients with acute ischemic stroke. J Neural Transm 2005; 112: 1371-1379.
41. Pennypacker KR, Hernandez H, Benkovic S, Morgan DG, Willing AE and Sanberg PR. Induction of presenilins in the rat brain after middle cerebral arterial occlusion. Brain Res Bull 1999; 48: 539-543.
42. Luchsinger JA. Type 2 diabetes, related conditions, in relation and dementia: an opportunity for prevention? J Alzheimers Dis 2010; 20: 723-736.
43. Wolff SP. Diabetes mellitus and free radicals Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Brit Med Bull 1993; 49: 642- 652.
44. Croxson SC and Jagger C. Diabetes and cognitive impairment: a community-based study of elderly subjects. Age Ageing 1995; 24: 421- 424.
45. Ott A, Stolk RP, Van Harskamp F, Pols H and Hofman A. Diabetes mellitus and the risk of dementia The Rotterdam Study. Neurology 1999; 53: 1937-1942.
46. Kroner Z. The relationship between Alzheimer's disease and diabetes: type 3 diabetes? Altern Med Rev 2009; 14: 373-379.
47. Plastino M, Fava A, Pirritano D, Cotronei P, Sacco N, Sperlì T, Spanò A, Gallo D, Mungari P, Consoli D and Bosco D. Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and Diabetes Mellitus type-2. J Neurol Sci 2010; 288: 112-116.
48. Birks J and Evans JG. Ginkgo biloba for cognitive impairment and dementia. The Cochrane Library, 2004.
49. Lingaerde O, Fφreland AR and Magnusson A. Can winter depression be prevented by Ginkgo biloba extract? A placebo-controlled trial. Acta Psychiatr Scand 1999; 100: 62-66.
50. Oken BS, Storzbach DM and Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 1998; 55: 1409-1415.
51. Ahlemeyer B and Krieglstein J. Pharmacological studies supporting the therapeutic use of Ginkgo biloba extract for Alzheimer's disease. Pharmacopsych 2003; 36: 8-14.
52. Mazza M, Capuano A, Bria P and Mazza S. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study. Eur J Neurol 2006; 13: 981-985.
53. Winter JC. The effects of an extract of Ginkgo biloba, EGb 761, on cognitive behavior and longevity in the rat. Physiol Behav 1998; 63: 425- 433.
54. Eckert A, Keil U and Scherping I. Stabilization of mitochondrial membrane potential and improvement of neuronal energy metabolism by Ginkgo biloba extract EGb 761. Ann N Y Acad Sci 2005; 1056: 474-485.
55. Yao Z, Drieu K and Papadopoulos V. The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid- deriveddiffusible neurotoxic ligands. Brain Res 2001; 889: 181-190.
56. Colciaghi F, Borroni B, Zimmermann M and Bellone C. Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts. Neurobiol Dis 2004; 16: 454-460.
57. Watanabe C, Wolffram S and Ader P. The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba. Proc Natl Acad Sci 2001; 98: 6577-6580.
58. DeKosky ST, Williamson JD and Fitzpatrick AL. Ginkgo biloba for prevention of dementia. JAMA 2008; 300: 2253-2262.
59. Weinmann S, Roll S, Schwarzbach C, Vauth C and Willich SN. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr 2010; 10: 14.
60. Hashimoto T and Yamada Y. Alkaloid biogenesis: molecular aspects. Ann Rev Plant Biol 1994; 45: 257-285.
61. Heinrich M and Teoh L. Galanthamine from snowdrop--the development of a modern drug against Alzheimer's disease from local Caucasian knowledge. J Ethnopharmacol 2004; 92: 147-162.
62. Loy C and Schneider L. Galantamine for Alzheimer's disease. The Cochrane Library, 2005.
63. Jackisch R, Förster S, Kammerer M, Rothmaier AK, Ehret A, Zentner J and Feuerstein TJ. Inhibitory potency of choline esterase inhibitors on acetylcholine release and choline esterase activity in fresh specimens of human and rat neocortex. J Alzheimers Dis 2009; 16: 635- 647.
64. Melo JB, Sousa C and Garção P. Galantamine protects against oxidative stress induced by amyloid-beta peptide in cortical neurons. Eur J Neurosci 2009; 29: 455-464.
65. Raskind MA, Peskind ER, Wessel T and Yuan W. Galantamine in AD A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54: 2261-2268.
66. Fisher AA and Davis MW. Prolonged QT interval, syncope, and delirium with galantamine. Ann Pharmacother 2008; 42: 278-283.
67. Chrusciel M and Varagić V. The effect of galantamine on the blood pressure of the rat. Br J Pharmacol Chemother 1966; 26: 295-301.
68. Ware MA, Adams H and Guy GW. The medicinal use of cannabis in the UK: results of a nationwide survey. Int J Clin Pract 2005; 59: 291- 295.
69. Eubanks LM, Rogers CJ, Beuscher AE, Koob GF, Olson AJ, Dickerson TJ and Janda KD. A molecular link between the active component of marijuana and Alzheimer's disease pathology. Mol Pharm 2006; 3: 773-777.
70. Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M and Izzo AA. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloidinduced toxicity in PC12 cells. J Neurochem 2004; 89: 134-141.
71. Hampson AJ, Grimaldi M, Axelrod J and Wink D. Cannabidiol and (-) Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 1998; 95: 8268-8273.
72. Esposito G, De Filippis D, Carnuccio R, Izzo AA and Iuvone T. The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/betacatenin pathway rescue in PC12 cells. J Mol Med 2006; 84: 253-258.
73. Weiss L, Zeira M, Reich S, Har-Noy M, Mechoulam R, Slavin S and Gallily R. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 2006; 39: 143- 151.
74. van Ours JC, Williams J, Fergusson D and Horwood LJ. Cannabis use and suicidal ideation. J Health Econ 2013; 32: 524-537.
75. Lev-Ran S, Aviram A, Braw Y, Nitzan U, Ratzoni G and Fennig S. Clinical correlates of cannabis use among adolescent psychiatric inpatients. Eur Psych 2012; 27: 470-475.
76. Thomas H. Psychiatric symptoms in cannabis users. Br J Psychiatry 1993; 163: 141-149.
77. Bieski IGC, Rios Santos F, de Oliveira RM, Espinosa MM, Macedo M, Albuquerque UP and de Oliveira Martins DT. Ethnopharmacology of medicinal plants of the pantanal region (mato grosso, Brazil). Evid Based Complement Alternat Med 2012; 2012: 272749.
78. Li S, Long J, Ma Z, Xu Z, Li J and Zhang Z. Assessment of the therapeutic activity of a combination of almitrine and raubasine on functional rehabilitation following ischaemic stroke. Curr Med Res Opin 2004; 20: 409-415.
79. Li Y and Ohizumi Y. Search for Constituents with Neurotrophic Factor-Potentiating Activity from the Medicinal Plants of Paraguay and Thailand. Yakugaku Zasshi 2004; 124: 417- 424.
80. Coulibaly AY, Sombie PAED, Tibiri A, Kiendrebeogo M, Compaore MMY, and Nacoulma OG. Protective Effect of Scoparia dulcis on Brain and Erythrocytes. Curr Res J Biol Sci 2011; 3: 254-261.
81. Pari L and Latha M. Protective role of Scoparia dulcis plant extract on brain antioxidant status and lipidperoxidation in STZ diabetic male Wistar rats. BMC Complem Altern Med 2004; 4: 16.
82. Ratnasooriya WD, Jayakody JR, Premakumara GA and Ediriweera ER. Antioxidant activity of water extract of Scoparia dulcis. Fitoterapia 2005; 76: 220-222.
83. Praveen TK, Dharmaraj S, Bajaj J, Dhanabal SP, Manimaran S, Nanjan MJ, Razdan R. Hepatoprotective activity of petroleum ether, diethyl ether, and methanol extract of Scoparia dulcis L. against CCl4-induced acute liver injury in mice. Indian J Pharmacol 2009; 41: 110-114.
84. Dillard CJ and German JB. Phytochemicals: nutraceuticals and human health. J Sci Food Agric 2000; 80: 1744-1756.
85. Zulfiker A, Ripa FA and Rahman MM. Antidiabetic and Antioxidant Effect of Scoparia dulcis in Alloxan induced Albino Mice. Int J Pharm Tech Res 2010; 2: 2527-2534.
86. Coulibaly AY, Kiendrebeogo M, Kehoe PG, Sombie PA, Lamien CE, Millogo JF and Nacoulma OG. Antioxidant and anti-inflammatory effects of Scoparia dulcis L. J Med Food 2011; 14: 1576-1582.
87. Ahmed M and Jakupovic J. Diterpenoids from Scoparia Dulcis. Phytochemistry 1990; 29: 3035-3037.
88. Hayashi T, Okamura K, Tamada Y, Iida A and Fujita T. A new chemotype of Scoparia dulcis. Phytochemistry 1993; 32: 349-352.
89. Adaikpoh MA. The protective role of Scoparia dulcis on tissue antioxidant defense system of rats exposed to cadmium. African J Biotech 2007; 6: 1192-1196.
90. Latha M and Pari L. Effect of an aqueous extract of Scoparia dulcis on blood glucose, plasma insulin and some polyol pathway enzymes in experimental rat diabetes. Braz J Med Biol Res 2004; 37: 577-586.
91. Li Y, Chen X, Satake M, Oshima Y and Ohizumi Y. Acetylated Flavonoid Glycosides Potentiating NGF Action from Scopariadulcis. J Nat Prod 2004; 67: 725-727.
92. Pari L and Venkateswaran S. Hypoglycaemic activity of Scopariadulcis L. extract in alloxan induced hyperglycaemic rats. Phytother Res 2002; 16: 662-664.
93. Phan MG, Phan TS, Matsunami K and Otsuka H. Chemical and biological evaluation on scopadulane- type diterpenoids from Scoparia dulcis of Vietnamese origin. Chem Pharm Bull 2006; 54: 546-549.
94. Lala PK and Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2001; 2: 149-156.
95. Martins SP and Takahashi CS. In vitro and in vivo study of the clastogenicity of the flavone cirsitakaoside extracted from Scoparia dulcis L. (Scrophulariaceae). Teratog Carcinog Mutagen 1998; 18: 293-302.
96. Gordon MH and An J. Antioxidant activity of flavonoids isolated from licorice. J Agric Food Chem 1995; 43: 1784-1788.
97. Kelley BJ and Knopman DS. Alternative medicine and Alzheimer's disease. Neurologist 2008; 14: 299-306.
98. Noble RL. The discovery of the vinca alkaloidschemotherapeutic agents against cancer. Biochem Cell Biol 1990; 68: 1344-1351.
99. Kulkarni RN, Baskaran K and Chandrashekara RS. Inheritance of morphological traits of periwinkle mutants with modified contents and yields of leaf and root alkaloids. Plant Breeding 1999; 118: 71-74.
100. Pezzuto JM. Plant-derived anticancer agents. Biochem Pharmacol 1997; 53: 121-133.
101. Chattopadhyay RR. A comparative evaluation of some blood sugar lowering agents of plant origin. J Ethnopharmacol 1999; 67: 367-372.
102. Singh SN, Vats P, Suri S, Shyam R and Kumria M. Effect of an antidiabetic extract of Catharanthus roseus on enzymic activities in streptozotocin induced diabetic rats. J Ethnopharmacol 2001; 76: 269-277.
103. Ferreres F, Pereira DM, Valentão P, Andrade PB, Seabra RM and Sottomayor M. New phenolic compounds and antioxidant potential of Catharanthus roseus. J Agric Food Chem 2008; 56: 9967-9974.
104. Pereira DM, Ferreres F, Oliveira J, Valentão P, Andrade PB, Sottomayor M. Targeted metabolite analysis of Catharanthus roseus and its biological potential. Food Chem Toxicol 2009; 47: 1349-1354.
105. Pereira DM, Ferreres F, Oliveira JM, Gaspar L, Faria J, Valentão P, Sottomayor M and Andrade PB. Pharmacological effects of Catharanthus roseus root alkaloids in acetylcholinesterase inhibition and cholinergic neurotransmission. Phytomedicine 2010; 17: 646-652
106. Zenk MH. Enzymatic synthesis of ajmalicine and related indole alkaloids. J Nat Prod 1980; 43: 438-451.
107. Demichel P, Gomond P and Roquebert J. alpha- Adrenoceptor blocking properties of raubasine in pithed rats. Br J Pharmacol 1982; 77: 449-454.
108. Jaleel CA, Gopi R, Manivannan P, Sankar B, Kishorekumar A and Panneerselvam R. Antioxidant potentials and ajmalicine accumulation in Catharanthus roseus after treatment with giberellic acid. Colloids Surf B Biointerfaces 2007; 60: 195-200.
109. Bedigian D, Seigler DS and Harlan JR. Sesamin, sesamolin and the origin of sesame. Biochem System Ecol 1985; 13: 133-139.
110. Hou RC, Huang HM, Tzen JT and Jeng KC. Protective effects of sesamin and sesamolin on hypoxic neuronal and PC12 cells. J Neurosci Res 2003; 74: 123-133.
111. Suja KP and Jayalekshmy A. Free radical scavenging behavior of antioxidant compounds of sesame (Sesamum indicum L.) in DPPH system. J Agric Food Chem 2004; 52: 912-915.
112. Hou RCW, Chen HL, Tzen JT and Jeng KC. Effect of sesame antioxidants on LPS-induced NO production by BV2 microglial cells. Neuroreport 2003; 14: 1815-1819.
113. MacRae WD and Towers GH. Biological activities of lignans. Phytochemistry 1984; 23: 1207-1220.
114. Moazzami A. Sesame Seed Lignans. J Amer Oil Chem Soc 2006; 83: 719-723.
115. Yoshida H and Takagi S. Effects of seed roasting temperature and time on the quality characteristics of sesame (Sesamum indicum) oil. J Sci Food Agric 1997; 75: 19-26.
116. Parihar VK, Prabhakar KR and Veerapur VP. Effect of sesamol on radiation-induced cytotoxicity in Swiss albino mice. Mut Res 2006; 611: 9-16.
117. Fresco P, Borges F and Diniz C. New insights on the anticancer properties of dietary polyphenols. Med Res Rev 2006; 26: 747-766.
118. Chang LW, Yen WJ, Huang SC and Duh PD. Antioxidant activity of sesame coat. Food Chem 2002; 78: 347-354.
119. Kuhad A and Chopra K. Effect of sesamol on diabetes-associated cognitive decline in rats. Exp Brain Res 2008; 185: 411-420.
120. Jiang Q, Christen S, Shigenaga MK and Ames BN. gamma-tocopherol, the major form of vitamin E in the US diet, deserves more attention. Am J Clin Nutr 2001; 74: 714-722.
121. Lemcke-Norojärvi M, Kamal-Eldin A, Appelqvist LA, Dimberg LH, Ohrvall M, and Vessby B. Corn and sesame oils increase serum gamma-tocopherol concentrations in healthy Swedish women. J Nutr 2001; 131: 1195-1201.
122. Sano M, Ernesto C and Thomas RG. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997; 336: 1216-1222.
123. Marder K. Vitamin E and donepezil for the treatment of mild cognitive impairment. Curr Neurol Neurosci Rep 2005; 5: 337-338.
124. Lee SY, Ha TY, Son DJ, Kim SR and Hong JT. Effect of sesaminol glucosides on beta-amyloid- induced PC12 cell death through antioxidant mechanisms. Neurosci Res 2005; 52: 330-341.
125. Togola A, Austarheim I, Theïs A, Diallo D and Paulsen BS. Ethnopharmacological uses of Erythrina senegalensis: a comparison of three areas in Mali, and a link between traditional knowledge and modern biological science. J Ethnobiol Ethnomed 2008; 4: 6.
126. Donfack JH, Nico FN and Ngamenib B. In vitro hepatoprotective and antioxidant activities of diprenylated isoflavonoids from Erythrina senegalensis (Fabaceae). Asian J Trad Med 2008; 3: 172-178.
127. Kaufman PB, Kirakosyan A, Cseke LJ and Duke JA. Biotechnology studies on isoflavone production in edible legumes. Recent Res Dev Plant Sci 2005; 3: 85-103.
128. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem 1996; 239: 70-76.
129. Florian T, Necas J, Bartosikova L, Klusakova J, Suchy V, Naggara EBE, Janostikova E and Bartosik T. Effects of prenylated isoflavones osajin and pomiferin in premedication on heart ischemia- reperfusion. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2006; 150: 93- 100.
130. Veselá D, Kubínová R, Muselík J, Zemlicka M and Suchy V. Antioxidative and EROD activities of osajin and pomiferin. Fitoterapia 2004; 75: 209-211.
131. Decker MW, Anderson DJ, Brioni JD, Donnelly- Roberts DL, Kang CH, O'Neill AB, Piattoni-Kaplan M, Swanson S and Sullivan JP. Erysodine, a competitive antagonist at neuronal nicotinic acetylcholine receptors. Eur J Pharmacol 1995; 280: 79-89.
132. Johnson CN, Roland A and Upton N. New symptomatic strategies in Alzheimer's disease. Drug Discovery Today: Therapeutic Strategies 2004; 1: 13-19.
133. Atsamo AD, Nguelefack TB, Datté JY and Kamanyi A. Acute and subchronic oral toxicity assessment of the aqueous extract from the stem bark of Erythrina senegalensis DC (Fabaceae) in rodents. J Ethnopharmacol 2011; 134: 697-702.
134. Ehlers JD and Hall AE. Cowpea (Vigna unguiculata L. Walp.). Field Crops Res 1997; 3: 187- 204.
135. Siddhuraju P and Becker K. The antioxidant and free radical scavenging activities of processed cowpea (Vigna unguiculata (L.) Walp.) seed extracts. Food Chem 2007; 101: 10-19.
136. Oboh G. Antioxidant properties of some commonly consumed and underutilized tropical legumes. European Food Res Tech 2006; 224: 61-65.
137. Graf E, Empson KL and Eaton JW. Phytic acid. A natural antioxidant. J Biol Chem 1987; 262: 11647-11650.
138. Contour-Ansel D and Torres-Franklin ML. Glutathione reductase in leaves of cowpea: cloning of two cDNAs, expression and enzymatic activity under progressive drought stress, desiccation and abscisic acid treatment. Ann Bot 2006; 98: 1279-1287.
139. Dalton DA, Joyner SL, Becana M, Iturbe-Ormaetxe I and Chatfield JM. Antioxidant defenses in the peripheral cell layers of legume root nodules. Plant Physiol 1998; 116: 37-43.
140. Segura-Campos MR and Chel-Guerrero LA. Purification of angiotensin I-converting enzyme inhibitory peptides from a cowpea ( Vigna unguiculata) enzymatic hydrolysate. Process Biochem 2011; 46: 864-872.
141. McGuinness B, Todd S, Passmore P and Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev 2009; 4: 4034.
142. Ohrui T, Matsui T, Yamaya M and Arai H. Angiotensin- Converting Enzyme Inhibitors and Incidence of Alzheimer's Disease in Japan. J Am Geriatr Soc 2004; 52: 649-650.
143. Gallardo G, Schlüter OM and Südhof TC. A molecular pathway of neurodegeneration linking α-synuclein to ApoE and Aβ peptides. Nat Neurosci 2008; 11: 301-308.
144. Ismail AM, Hall AE and Close TJ. Purification and partial characterization of a dehydrin involved in chilling tolerance during seedling emergence of cowpea. Plant Physiol 1999; 120: 237-244.